Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04327024 · ClinicalTrials.gov registry record · Phase 2
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT04327024 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 159 participants.
The verdict
NCT04327024, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
Interventions
- DRUG Allopurinol
- DRUG Verinurad
- DRUG Placebo for verinurad
- DRUG Placebo for allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-05-19 |
| Est. Completion | 2022-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04327024
The ClinicalTrials.gov registry entry for NCT04327024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Allopurinol is the first listed.
NCT04327024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04327024 about?
NCT04327024 is a clinical study titled "Study of Verinurad in Heart Failure With Preserved Ejection Fraction". International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
What is the current status of trial NCT04327024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2020-05-19. Estimated completion is 2022-04-29.
What interventions are being tested in trial NCT04327024?
The interventions under investigation include: Allopurinol (DRUG), Verinurad (DRUG), Placebo for verinurad (DRUG), Placebo for allopurinol (DRUG).
Who is sponsoring clinical trial NCT04327024?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.